EGFR and lung adenocarcinoma: Recently, it was reported that high levels of NKCC1 expression predict poor clinical outcomes for lung adenocarcinoma patients and an epidermal growth factor receptor (EGFR)‐mutated subgroup (Sun et al., 2016).